Home/Our innovation /Focus areas/Oncology/Oncology newsroom /ASCO/EHA 2023
ASCO/EHA 2023
Welcome to the Janssen Oncology Virtual Newsroom.
lebowitz_qc_v3.jpg
Peter Lebowitz, M.D., Ph.D.
Global Therapeutic Area Head Oncology
Janssen Research & Development, LLC
brewer_qc_v2.jpg
Tyrone Brewer
U.S. President, Oncology
Janssen Biotech, Inc
Latest news
Oncology
Janssen to Highlight Scientific Advances and Commitment to Transform Cancer Care at ASCO and EHA with More than 90 Presentations Showcasing Robust, Differentiated Portfolio and Pipeline in Hematologic Malignancies and Solid Tumors
May 18, 2023
United States
Learn more
Abstract chart and data research
Oncology
Janssen Presents Longer-Term Data for TECVAYLI® (teclistamab-cqyv) Showing a Duration of Response of 22 Months in Patients with Relapsed or Refractory Multiple Myeloma
June 5, 2023
United States
Learn more
Oncology
CARVYKTI® (ciltacabtagene autoleucel) Reduces Risk of Disease Progression or Death by 74 Percent in Earlier-Line Multiple Myeloma Treatment in the Landmark Phase 3 CARTITUDE-4 Study
June 5, 2023
United States
Learn more
Oncology
Janssen Announces BALVERSA® (erdafitinib) Improved Overall Survival Versus Chemotherapy in Patients with Metastatic or Unresectable Urothelial Carcinoma and Selected Fibroblast Growth Factor Receptor Gene Alterations After Prior Anti-PD-(L)1 Treatment
June 5, 2023
United States
Learn more
Oncology
New Long-Term Data from the CHRYSALIS Study Show Median PFS Not Reached after 33.6 Months of Follow Up with First-Line Use of RYBREVANT® (amivantamab-vmjw) and Lazertinib Combination Therapy in Patients with Treatment-Naïve EGFR-Mutated Advanced NSCLC
June 4, 2023
United States
Oncology
Janssen Presents First-Ever Results from Dual Bispecific Combination Study Showing 96 Percent Overall Response Rate in Patients with Relapsed or Refractory Multiple Myeloma
June 3, 2023
United States
Learn more
Oncology
Janssen Presents Longer-Term Talquetamab Follow-Up Data Showing Overall Response Rates of More Than 70 Percent in Heavily Pretreated Patients with Multiple Myeloma
June 3, 2023
United States
Learn more
Featured stories
precision_onc.png
Perspective: Delivering precision medicine for bladder cancer through collaboration
Learn more
nature.png
How to get in front of prostate cancer
Learn more
biopharma_dive_podcast.png
Breaking down barriers: how bladder cancer innovations benefit patients and treatments for other diseases
Learn more
targeted_onc.png
Biomarker testing in non-small cell lung cancer.
Learn more
nature_2.png
An integrated approach combining prevention, interception and treatment to tackle lung cancer
Learn more
stat.png
In relentless pursuit of curing multiple myeloma
Learn more
jnj.png
Johnson & Johnson Oncology
Learn more
biopharma_dive_2_v2.png
Changing the trajectory of blood cancers with transformational and potentially curative therapies at ASH
Learn more